Stathmin 1 Expression in Prostate Cancer
Author Information
Author(s): Shi Yingli, Yeh Yunshin, Cheng Siyuan, Gu Xin, Yang Shu, Li Lin, Khater Nazih P., Kasper Susan, Yu Xiuping
Primary Institution: Louisiana State University Health Sciences Center at Shreveport
Hypothesis
This study investigates the role of stathmin 1 (STMN1) in aggressive prostate cancer and its potential as a prognostic marker.
Conclusion
The study found that elevated STMN1 expression is associated with high Gleason scores and poor clinical outcomes in prostate cancer patients.
Supporting Evidence
- Elevated STMN1 expression correlates with high Gleason Scores and poor clinical outcomes.
- STMN1 levels were significantly higher in neuroendocrine prostate cancer compared to adenocarcinoma.
- Patients with high STMN1 expression exhibited a lower overall survival rate.
Takeaway
This study shows that a protein called STMN1 is found in higher amounts in aggressive prostate cancer, which could help doctors predict how serious the cancer is.
Methodology
The study used bioinformatics analysis, western blotting, and immunohistochemical staining to evaluate STMN1 expression in prostate cancer samples.
Participant Demographics
The study included human prostate specimens classified by pathologists based on histology and Gleason grades.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website